Pfizer CFO Dave Denton to Step Down in August 2026 Amid Leadership Transition
Pfizer announced CFO Dave Denton will depart on August 15, 2026, to join the consumer goods sector, with Cecile Guegan named interim CFO. The company reaffirmed its 2026 revenue guidance of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00. Denton oversaw major acquisitions like Seagen during Pfizer’s post-pandemic transition. The news caused a 2.74% stock drop and heightened investor concern over leadership continuity and cost control, though the broader market rose.
Cross-source coverage
Wire timeline
Pfizer Reaffirms FY 2026 Outlook Amid CFO Leadership Change
Pfizer Inc. (NYSE: PFE) announced on June 18, 2026 that CFO Dave Denton will step down effective August 15 to pursue an opportunity in the consumer goods sector. Cecile Guegan will serve as Interim CFO starting August 16 while the company conducts a comprehensive search for a permanent replacement. Simultaneously, Pfizer reaffirmed its full-year 2026 outlook, targeting total revenues between $59.5 billion and $62.5 billion and adjusted diluted earnings per share of $2.80 to $3.00. The guidance assumes adjusted gross margins in the mid-70s range combined with cost discipline and investment. The company also highlighted its robust annual dividend yield of 6.96%, noting its inclusion among high-yield Fortune 500 stocks. The announcement comes as Pfizer continues to navigate post-pandemic demand dynamics for its COVID-19 products.
Yahoo FinancePfizer CFO Dave Denton to Step Down Effective August 15; Interim Successor Named
Pfizer (NYSE: PFE) announced on June 18, 2026, that Chief Financial Officer Dave Denton will step down on August 15 to pursue a new opportunity in consumer goods. Cecile Guegan, currently Senior Vice President of Finance for the Global Biopharmaceutical Business, has been appointed interim CFO effective August 16. A search for a permanent successor is underway. Chairman and CEO Albert Bourla thanked Denton for his leadership during major acquisitions, including Seagen, Biohaven, and Metsera, which are expected to support long-term growth. Guegan brings over two decades of experience at Pfizer, including overseeing Seagen's integration in 2024. The article also positions Pfizer as one of the most undervalued NYSE stocks and includes promotional content for an AI stock report.
Yahoo FinancePfizer Stock Falls as CFO Transition Tests Confidence in 2026 Outlook
On June 18, 2026, Pfizer's stock closed at $25.21, down 2.74%, following the announcement that CFO Dave Denton will depart in August. Trading volume surged 85% above the three-month average, reflecting investor concern over leadership continuity and the execution of 2026 revenue and EPS guidance. Cecile Guegan will serve as interim CFO while a permanent successor is sought. The decline was part of a broader biopharma sector dip, with Merck and Bristol-Myers Squibb also falling. Despite recent pipeline approvals (Hympavzi, VEPPANU), the CFO transition raises immediate doubts about Pfizer's cost-control efforts and earnings recovery. The broader market was positive, with the S&P 500 up 1.05% and Nasdaq up 1.91%.
Yahoo FinancePfizer CFO Dave Denton to Step Down in August 2026
Pfizer announced that Chief Financial Officer Dave Denton will step down on August 15, 2026, to take a position in consumer goods. He will be succeeded on an interim basis by Cecile Guegan, currently senior vice president of finance for Pfizer's global biopharmaceutical business, effective August 16. The company will conduct a search for a permanent CFO, considering both internal and external candidates. Pfizer Chairman and CEO Albert Bourla praised Denton for guiding the company through major acquisitions, including Seagen, Biohaven, and Metsera. An SEC filing confirmed Denton notified Pfizer of his decision on June 16 and that his departure is unrelated to the company's financial or operating results. Guegan, who joined Pfizer in 2005, played a role in integrating Seagen in 2024. Pfizer stock fell 1.6% in premarket trading following the announcement.
Yahoo FinancePfizer CFO Dave Denton Departs for Consumer Goods Sector
Pfizer announced that CFO Dave Denton will step down on August 15, 2026, to pursue a professional opportunity in the consumer goods industry. The company appointed Cecile Guegan, SVP of finance for the global biopharmaceutical business, as interim CFO effective August 16, while launching an internal and external search for a permanent successor. Denton joined Pfizer in 2022 from Lowe's and oversaw major acquisitions including Seagen, Biohaven, and Metsera during a period of transition from pandemic-era revenue highs. The departure comes amid rising skepticism toward vaccines and drugmakers, partly driven by the Make America Healthy Again movement, and as Pfizer adjusts to lower demand for its COVID-19 products. Despite challenges, Pfizer's oncology drugs are showing strong growth, and the company is expected to attract high-caliber CFO candidates.
Yahoo Finance